IRD (23) FULC (34) BNTC (30) GLSI (35) ⌘ Pro Terminal →

Vogenx Inc (VOGX) — RQD Stock Rating Cockpit

$20.25 +1.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.27

Vogenx Inc (VOGX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $295.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VOGX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Vogenx Inc (NASDAQ: VOGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $20.25 (+1.66% 1D, market cap $295.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VOGX compare to IRD and FULC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $303.7M) and FULC (Fulcrum Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $288.0M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VOGX?

▼

Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $0 in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $20.27 (+0.11%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOGX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY VOGX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.14-7.1% Next Q

Q2 (-2Q)

Grade D$15.92+8.9% Next Q

Q3 (-1Q)

Grade D$17.34+16.8% Next Q

Current

Grade D$20.25-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VOGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VOGX currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.49) and Max Pain ($21.26) forces dealer call-delta covering toward $40.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VOGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VOGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

51.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE29% OF RANGE

L: $13$20.25H: $38

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on VOGX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like VOGX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOGX)

✓Walkthrough of VOGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VOGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.77%📐 HORIZONTAL RANGE

2026-11-02O $18.92H $20.25L $18.92C $20.25VOL 75.4K

RES: $43.72SUP: $4.16SMA50: $24.49SMA200: $23.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VOGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VOGX Butterfly Map → + Track VOGX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VOGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VOGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VOGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOGX)

Health Care Rank #411 of 1016 ⚔️ IRD vs VOGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VOGX vs. IRD, FULC, BNTC, GLSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vogenx Inc (VOGX) ranks #411 by composite RQD confidence (45/100, grade D) and #519 by equity capitalization ($295.9M). Within this direct 5-issuer industry benchmark cohort, VOGX leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VOGX ACTIVE Vogenx Inc	D	45/100	—	—	—	+1.66%	$295.9M	Benchmark Subject
IRD Opus Genetics Inc.	E	23/100	—	—	-35.0%	+0.55%	$303.7M	/ird-vs-vogx →
FULC Fulcrum Therapeutics Inc.	E	34/100	—	—	-35.0%	-1.59%	$288.0M	/fulc-vs-vogx →
BNTC Benitec Biopharma Inc.	E	30/100	—	—	-35.0%	-1.02%	$308.1M	/bntc-vs-vogx →
GLSI Greenwich LifeSciences Inc.	D-	35/100	—	—	-35.0%	-8.37%	$278.9M	/glsi-vs-vogx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001903784

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vogenx Inc (VOGX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, VOGX closed FY2025 with $681.2K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$681.2K	—

3. VOGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VOGX compare to IRD and FULC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VOGX?

Where is VOGX trading relative to its 50-day, 200-day, and 52-week technical levels?

VOGX last traded at $20.25 (+1.66% on volume of 45,089 shares), positioning the stock -17.31% below its 50-day simple moving average ($24.49) and -14.77% below its 200-day simple moving average ($23.76). Across its 52-week range of $12.95 to $38.41, VOGX sits at the 28.7% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.72 to $22.78).

VOGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VOGX stock right now?

Vogenx Inc (VOGX) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is VOGX's 12-month price target and RQD AI Jury consensus?

VOGX's 12-month base price target is $19.07 (range $14.87 to $40.33), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VOGX RQD Cockpit VOGX 12M Forecast VOGX Earnings & Move VOGX Dividends & DRIP VOGX Insiders & 13F VOGX Whale Options VOGX Profit Sankey VOGX News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VOGX — Vogenx Inc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:16:49Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VOGX scores 45 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 10 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 5 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are institutional flow, insider conviction, and macro fit, while the balance sheet is the relative strength. The 0% ROIC and 0% FCF yield indicate the cash-generation engine is not visible in the source data, so the investment case rests on factors other than current earnings power. The Altman Z of 2.5 and Piotroski F of 6/9 provide some forensic comfort, but they do not offset the absence of demonstrated returns. Any upside would depend on a sentiment or catalyst-driven re-rating rather than on fundamentals currently reflected in the data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the lead item (Stock Titan, flagged as a green CATALYST) reports that Vogenx starts a trial addressing blood-sugar drops after weight-loss surgery, for which no FDA-approved treatment exists. Three additional items (Benzinga, Traders Union twice) are yellow market-wire entries: one lists VOGX among health care stocks moving in pre-market trading, and two are generic price and technical-analysis pages.

Per the Butterfly Supply-Chain Graph, a proprietary LIQUIDITY_TAILWIND signal is BEARISH with severity 94 and a Macro Tailwind Score of 18/100. The signal cites True Net Liquidity contracting -0.64% over four weeks to $5,746B, a 2 bps widening in ICE BofA High-Yield OAS, and a 6.1 z-score macro divergence. It also cites VOGX's Net Liquidity Elasticity of 6.00x Beta (r=+0.30). Key risk watch items are this macro headwind and the absence of demonstrated earnings.

Open Questions

What are VOGX's revenue, operating income, and net income figures in dollars beyond the reported $0.0M, and what drives the 0% margins?
What is the company's debt in dollar terms, given that the FY 2025 debt field is N/A despite a Debt/Equity of 0.5?
What is the status and timeline of the post-surgery blood-sugar trial referenced in the lead news item, and what is its stage or funding?
Who are the institutional and insider holders, and what are the 13F and Form 4 positions behind the 5/20 whale-flow and 9/20 insider pillars?
What are the TTM earnings, forward estimates, and any analyst coverage that would allow valuation to be assessed?

VOGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vogenx Inc (VOGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VOGX Debate Forum (3) ↓

🟢 CATALYST Stock Titan • 14h ago

Blood-sugar drops after weight-loss surgery have no FDA-approved treatment. Vogenx starts a trial.

Stock Titan report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 17h ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 20h ago

Vogenx Inc Stock Price Today | VOGX Live Chart & News

Traders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 23h ago

Live Vogenx Inc (VOGX) Technical Analysis

Traders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 11d ago

Why QuantumScape Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

QuantumScape rises 9.1% after narrower loss and new solid-state battery production plans; SHFS leads gainers while POM and others fall premarket.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 18d ago

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

There are currently no therapeutics approved by the U. Food and Drug Administration for the treatment of PBH.

Read Full Source ↗

🟢 CATALYST Benzinga • 18d ago

Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia

Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgeryRALEIGH, NC /

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VOGX Bull vs. Bear Conversation Board — What's Your Call at $20.25?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VOGX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $17.53 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VOGX (D • RQD 45/100) a Buy at $19.92?

Welcome to the VOGX (Vogenx Inc) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $16.53 (-17.0%)

Spot @ $19.92

Pump the brakes on VOGX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VOGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Vogenx Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $23.90 (+20.0%)

Spot @ $19.92

VOGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VOGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.92 (52-wk range $12.95 - $38.41), any beat on forward guidance forces shorts and underweight funds to chase.